NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, March 31, 2025 (GLOBE NEWSWIRE) — New Stratus Energy Inc. (TSX.V – NSE) (“New Stratus”, “NSE” or the “Corporation”) is pleased to announce that it has priced and increased the size of its previously announced brokered private placement […]
(NASDAQ:VANI), Successful initial administration and full enrollment in first-in-human LIBERATE-1(TM) study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025 Positive NPM-139 (semaglutide implant) preclinical weight loss data comparable to injections of semaglutide, active ingredient in Ozempic(R)/Wegovy(R), with potential for once-yearly dosing Additional $8.25M equity financing which secures solid
(NASDAQ:PVLA), Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic skin diseases Top-line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN(TM) 3.9%
(NYSE:FCN), WASHINGTON, March 31, 2025 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that its Board of Directors elected Eric T. Steigerwalt and Janet H. Zelenka as independent directors of the Company, effective March 25, 2025, following the action of the Board to increase its overall size to 11 from nine. Mr. Steigerwalt,
(TSX-V:DGHI),(NASDAQ:DGHI),(NASDAQ:DGXX),(TSX-V:DGX), MIAMI, March 31, 2025 (GLOBE NEWSWIRE) — Digi Power X Inc. (“Digi Power X” or the “Company“) (Nasdaq: DGXX / TSXV: DGX), an innovative energy infrastructure company that develops cutting-edge data centers, is pleased to provide a summary of the Company's audited financial results for the year ended December 31, 2024 (all amounts in
(NASDAQ:MAZE), MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025 Raised $140 Million in Gross Proceeds in Upsized IPO in February 2025, Providing Expected Cash Runway into H2 2027 SOUTH SAN FRANCISCO, Calif.,
(NASDAQ:AVXL), NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present
(TSX-V:RVG),(OTC US:RVLGF),(Other OTC:RVLGF), TORONTO, March 31, 2025 (GLOBE NEWSWIRE) — Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”) is pleased to announce compelling results from a Preliminary Economic Assessment (“PEA”) on the Company's Mercur Gold Project (“Mercur” or the “Project”) in Utah, U.S.A. Furthermore, the Project's favorable mineral tenure, straightforward design
$1.35 billion first-ever securitization of internet identity services assets Hoplon Capital LLC (“Hoplon”), a financial services holding company, is pleased to announce both the formation of Vistina Structured Credit, LLC (“Vistina”) and the completion of Vistina's inaugural structured financing advisory mandate. Vistina is led by experienced structured finance professionals Robert Horowitz and Peter Forshee, both
Isomorphic Labs will utilise the funding to further power its AI drug designengine through frontier AI research and development and to scale and progress its drug candidate pipeline. Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $600 Million in its first external funding round. The financing round is led